Edwards Lifesciences (NYSE:EW) Upgraded at Wells Fargo & Company

Wells Fargo & Company upgraded shares of Edwards Lifesciences (NYSE:EWFree Report) from an equal weight rating to an overweight rating in a report released on Friday morning, MarketBeat.com reports. They currently have $94.00 target price on the medical research company’s stock.

Several other equities research analysts have also recently weighed in on the company. Stifel Nicolaus dropped their target price on Edwards Lifesciences from $87.00 to $70.00 and set a hold rating for the company in a report on Thursday, October 26th. StockNews.com raised shares of Edwards Lifesciences from a hold rating to a buy rating in a research note on Monday, January 22nd. SVB Leerink started coverage on shares of Edwards Lifesciences in a report on Monday, October 16th. They issued a market perform rating and a $75.00 price target on the stock. Evercore ISI downgraded shares of Edwards Lifesciences from an outperform rating to an in-line rating and lowered their price objective for the company from $80.00 to $77.00 in a research note on Thursday, January 4th. Finally, Piper Sandler cut their target price on Edwards Lifesciences from $83.00 to $68.00 and set a neutral rating on the stock in a research note on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of Hold and a consensus target price of $84.19.

View Our Latest Analysis on Edwards Lifesciences

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $86.09 on Friday. The company has a quick ratio of 2.45, a current ratio of 3.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $52.21 billion, a PE ratio of 36.79, a PEG ratio of 4.74 and a beta of 1.04. The company’s fifty day moving average is $73.83 and its 200 day moving average is $73.54. Edwards Lifesciences has a 52 week low of $60.57 and a 52 week high of $94.87.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,660 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.30, for a total value of $565,498.00. Following the transaction, the insider now directly owns 213,794 shares of the company’s stock, valued at $13,960,748.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Larry L. Wood sold 8,660 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $65.30, for a total transaction of $565,498.00. Following the completion of the sale, the insider now owns 213,794 shares of the company’s stock, valued at approximately $13,960,748.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daveen Chopra sold 3,500 shares of the company’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $70.00, for a total value of $245,000.00. Following the completion of the sale, the vice president now owns 23,950 shares of the company’s stock, valued at $1,676,500. The disclosure for this sale can be found here. In the last ninety days, insiders sold 132,283 shares of company stock worth $9,714,586. Insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Vanguard Group Inc. boosted its position in shares of Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock worth $3,577,163,000 after purchasing an additional 325,808 shares during the period. State Street Corp lifted its position in shares of Edwards Lifesciences by 0.4% in the second quarter. State Street Corp now owns 27,053,304 shares of the medical research company’s stock valued at $2,551,938,000 after acquiring an additional 108,102 shares in the last quarter. Capital International Investors grew its position in shares of Edwards Lifesciences by 4.9% during the second quarter. Capital International Investors now owns 27,015,032 shares of the medical research company’s stock worth $2,548,023,000 after purchasing an additional 1,255,926 shares in the last quarter. Alliancebernstein L.P. raised its stake in Edwards Lifesciences by 0.3% during the 2nd quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company’s stock valued at $1,934,919,000 after purchasing an additional 66,763 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in Edwards Lifesciences by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after purchasing an additional 1,390,427 shares in the last quarter. 79.25% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Read More

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.